Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Research protocols vary, but a common approach involves administering BPC-157 once or twice daily
Report any suspected side effects to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk
The majority of BPC-157 research has been conducted in Wistar and Sprague-Dawley rat models, covering gastric ulcer induction (ethanol and NSAID models), Achilles tendon transection, ligament crush injuries, and various organ lesion protocols including liver, pancreas, and brain
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
